IE
ARTV

Israel Englander’s Artiva Biotherapeutics ARTV Stock Holding History

Israel Englander’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-123,270
Closed -$794K – 6506
2026
Q1 		$794K Sell
123,270
-93,827
-43% -$464K ﹤0.01% 4539
2025
Q4 		$931K Sell
217,097
-45,063
-17% -$170K ﹤0.01% 4535
2025
Q3 		$752K Sell
262,160
-64,907
-20% -$174K ﹤0.01% 4830
2025
Q2 		$494K Buy
+327,067
New +$687K ﹤0.01% 4923

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Israel Englander's ARTV Position: Q2 2026 in Review

Israel Englander sold out of Artiva Biotherapeutics (ARTV) in Q2 2026, closing a stake of 123,270 shares — an estimated $794K sold.

Israel Englander first reported a position in ARTV in Q2 2025 and held it in 4 quarters. The position peaked at $931K in Q4 2025. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Israel Englander reported no remaining Artiva Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 123,270 Artiva Biotherapeutics shares in Q2 2026, an estimated $794K.
  • Israel Englander first reported a position in Artiva Biotherapeutics in Q2 2025 and held it in 4 quarters.
  • Israel Englander's Artiva Biotherapeutics position peaked at $931K in Q4 2025.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.